New Zealand’s Medsafe Grants Provisional Approval for Novavax’ COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution in New Zealand ...
Read moreNuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution in New Zealand ...
Read moreManuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 ...
Read morePublication of initial primary analysis highlights NVX-CoV2373 cross-protection against B.1.351 variant prevalent in South Africa during ...
Read morePREVENT-19 clinical trial expanded to assess the efficacy, safety and immunogenicity of NVX-CoV2373 for the prevention ...
Read moreModerna, Inc. today announced that it has entered into an agreement with Sanofi for fill/finish sterile manufacturing ...
Read moreVaccine candidate demonstrates high efficacy at 77% in a study of children aged 5-17 months conducted ...
Read moreNovavax, Inc. announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing ...
Read moreModerna, Inc. and Catalent, Inc. today announced the expansion of their strategic collaboration to dedicate a ...
Read moreCrossover allows participants to continue in trials and remain blinded Ensures that all trial participants receive ...
Read moreNovavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the UK ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.